EARNINGS2020 Earnings Calendar: When Do Top Companies Report This Quarter?By Steve FiorilloMar 26, 2020 1:12 PM EDT
EARNINGS2020 Earnings Calendar: When Do Top Companies Report This Quarter?By Steve FiorilloMar 26, 2020 1:12 PM EDT
PRESS RELEASESNew England Journal Of Medicine Publishes Results From Pivotal Phase 3 BELIEVE Trial Of Reblozyl (luspatercept-aamt) In Adult Patients With Beta ThalassemiaBy Business WireMar 26, 2020 6:59 AM EDT
PRESS RELEASESBristol Myers Squibb To Announce Results For First Quarter 2020 On May 7, 2020By Business WireMar 26, 2020 6:58 AM EDT
PRESS RELEASESU.S. Food And Drug Administration Approves Bristol Myers Squibb's ZEPOSIA® (ozanimod), A New Oral Treatment For Relapsing Forms Of Multiple SclerosisBy Business WireMar 26, 2020 6:30 AM EDT
PRESS RELEASESBristol-Myers Squibb Postpones April 2, 2020 Investor DayBy Business WireMar 23, 2020 6:59 AM EDT
PRESS RELEASESBristol Myers Squibb Appoints Elizabeth Mily As Executive Vice President, Strategy & Business DevelopmentBy Business WireMar 18, 2020 6:59 AM EDT
PRESS RELEASESKitov Announces Pricing Of $6.0 Million Public OfferingBy GlobeNewswireMar 12, 2020 8:00 AM EDT
PRESS RELEASESU.S. Food And Drug Administration Approves Opdivo® (nivolumab) Yervoy® (ipilimumab) For Patients With Hepatocellular Carcinoma (HCC) Previously Treated With SorafenibBy Business WireMar 11, 2020 6:59 AM EDT
INVESTINGBristol-Myers Named a Bank of America Top Pick Amid Coronavirus FalloutBy Tony OwusuMar 5, 2020 8:30 AM EST
PRESS RELEASESVoluntis And Bristol-Myers Squibb To Co-Develop Digital Therapeutics For OncologyBy Business WireMar 3, 2020 5:30 PM EST
PRESS RELEASESBristol‑Myers Squibb Announces Dividend IncreaseBy Business WireMar 2, 2020 4:16 PM EST
PRESS RELEASESKitov Pharma Expands Planned NT-219 Clinical Program For Difficult To Treat CancersBy GlobeNewswireFeb 24, 2020 9:00 AM EST
PRESS RELEASES Bristol-Myers Squibb To Hold Investor Day On April 2By Business WireFeb 19, 2020 6:59 AM EST
PRESS RELEASESOpdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Continued Survival Benefit At 42-Month Follow-up In Patients With Previously Untreated Advanced Or Metastatic Renal Cell CarcinomaBy Business WireFeb 15, 2020 1:00 PM EST
JIM CRAMERColored by Coronavirus: Cramer's 'Mad Money' Recap (Friday 2/14/20)By Scott RuttFeb 14, 2020 8:32 PM EST
PRESS RELEASESMultinational Inflammatory Bowel Disease Survey Uncovers Striking Differences In Patients' And Physicians' Treatment Goals And Disease Management ExpectationsBy Business WireFeb 14, 2020 6:30 AM EST
PRESS RELEASESU.S. Food And Drug Administration (FDA) Accepts For Priority Review Bristol-Myers Squibb's Biologics License Application (BLA) For Lisocabtagene Maraleucel (liso-cel) For Adult Patients With Relapsed Or Refractory Large B-Cell LymphomaBy Business WireFeb 13, 2020 6:59 AM EST
MARKETSStocks Close at Record Highs as Rally Rolls for a Fourth DayBy Joseph WoelfelFeb 6, 2020 2:39 PM EST
INVESTINGBristol-Myers Tops Q4 Earnings Forecast as Celgene Takeover Boosts Bottom LineBy Martin BaccardaxFeb 6, 2020 9:36 AM EST
MARKETSQualcomm, Coronavirus, Tariffs, Twitter and Peloton - 5 Things You Must Know ThursdayBy Joseph WoelfelFeb 6, 2020 7:33 AM EST
